Chelerythrine enhances anti-fungi immunity in Caenorhabditis elegans via DAF-16 and NHR-49 mediated fatty acid metabolism
-
By
-
Shenyuan Fan
-
Guohui Bai
-
Tingting Zhong
-
Yi Xiao
-
Yuan Tian
-
June 9, 2026
-
Clinical Scorecard: Chelerythrine Boosts Fungal Immunity in Caenorhabditis elegans Through DAF-16 and NHR-49 Mediated Fatty Acid Metabolism
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Activation of DAF-16/FoxO pathway and NHR-49-mediated fatty acid metabolism (ensure direct sourcing). |
| Target Population | |
| Care Setting | |
Key Highlights
- Chelerythrine extends lifespan of C. elegans infected with C. albicans.
- Inhibition of C. albicans proliferation without reducing intestinal fungal burden.
- Activation of FoxO and fatty acid metabolism pathways confirmed through transcriptomic analysis.
- DAF-16 and NHR-49 are critical for the protective effects of Chelerythrine.
Guideline-Based Recommendations
Diagnosis
Management
- Current first-line therapy includes azole drugs; new strategies are needed due to rising resistance (ensure direct sourcing).
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Remove unsupported claims about Chelerythrine's therapeutic potential.
Clinical Best Practices
Related Resources & Content
